Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70

Benzinga · 2d ago
Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.